Please assess the completion status of the following clinical trial:

Trial Title: Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures.~2. Patients with RE classified into LA classification Grade A, B, C or D by Endoscopy despite of at least 8-week treatment using standard doses of PPIs.~3. Patients must fulfill at least one of the following criteria such as (i) RE with LA grade C/D at Endoscopy on visit 1 and/or history of RE with LA grade C/D, (ii) RE was diagnosed more than 1 year before visit 1.~4. Patients who are able to complete the Patient Diary~Exclusion Criteria:~1. Male or female aged less than 20 years at the time of informed consent.~2. Patients with current evidence of the gastrointestinal diseases/conditions such as esophageal stricture to interfere with the evaluation of the study etc~3. Gastric or duodenal ulcer verified by Endoscopy within 12 weeks before randomisation.~4. Previous esophageal, gastric or duodenal surgery except simple closure of perforated ulcer, simple endoscopic treatment with simple operation etc~5. Current or historical evidence (within 12 weeks prior to randomisation) of the diseases/conditions as judged to interfere with the evaluation of the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- D961H 20mg twice daily (Type: EXPERIMENTAL): Double-blinded
- D961H 20mg once daily (Type: ACTIVE_COMPARATOR): Double-blinded

Based on this trial design, predict the completion outcome and termination type (if applicable).